Abstract
Deposition of amyloid-beta (Aβ) peptides has been shown to induce the release of inflammatory factors by activated microglia and brain infiltrating monocytes/macrophages. Interestingly, the enzyme transglutaminase 2 (TG2) has been shown to play a key role in neuroinflammation and regulation of transcription factors involved in immunomodulation. In this study, we aimed to better elucidate the mechanisms underlying TG2 involvement in the pro-inflammatory signaling pathway activated by fibrillar Aβ1-42 in THP-1 monocytes. Cell exposure for 24 h to 500 nM Aβ1-42, induced the up-regulation of CD14, CD16, and TG2, suggesting THP-1 cell functional activation. Aβ1-42 also increased the production of reactive oxygen species, that was reduced by the pre-incubation with genistein (25 µg/ml), a soy isoflavone with antioxidant properties. Moreover, IL-1β and IL-6 mRNA transcript and protein levels were eightfold increased in Aβ1-42-treated THP-1 monocytes. Interestingly, these effects were significantly reduced by R283 (~45%), a specific inhibitor of TG activity, and genistein (~40%). Aβ1-42 induced the activation of p54/p46 JNK, as well as ERK 1/2 at a lower extent. The inactivation of ERK1/2 signalling pathway, but not JNK, by either genistein or U0126, a MEK1/2 inhibitor, was not able to blunt Aβ1-42-induced TG2 up-regulation, that, instead, was significantly reduced by R283. Aβ1-42 also induced AP-1 activation that was not significantly affected by genistein or U0126, while was strongly reduced by R283. Our preliminary findings first suggest that TG2 up-regulation is involved in the pro-inflammatory activation of THP-1 monocytes induced by Aβ1-42 via AP1/JNK signalling pathways.
Keywords:
AP1; Amyloid-beta1–42; Cytokines; R283; THP-1 monocytes; Transglutaminase 2.
MeSH terms
-
Amyloid beta-Peptides / antagonists & inhibitors
-
Amyloid beta-Peptides / pharmacology*
-
Butadienes / pharmacology
-
Cell Survival / drug effects
-
Enzyme Inhibitors / pharmacology
-
GPI-Linked Proteins / genetics
-
GPI-Linked Proteins / metabolism
-
GTP-Binding Proteins / antagonists & inhibitors
-
GTP-Binding Proteins / genetics*
-
GTP-Binding Proteins / metabolism
-
Gene Expression Regulation
-
Genistein / pharmacology
-
Humans
-
Interleukin-1beta / genetics
-
Interleukin-1beta / metabolism
-
Interleukin-6 / genetics
-
Interleukin-6 / metabolism
-
Lipopolysaccharide Receptors / genetics
-
Lipopolysaccharide Receptors / metabolism
-
MAP Kinase Kinase 4 / genetics*
-
MAP Kinase Kinase 4 / metabolism
-
Mitogen-Activated Protein Kinase 1 / genetics
-
Mitogen-Activated Protein Kinase 1 / metabolism
-
Mitogen-Activated Protein Kinase 3 / genetics
-
Mitogen-Activated Protein Kinase 3 / metabolism
-
Nitriles / pharmacology
-
Peptide Fragments / antagonists & inhibitors
-
Peptide Fragments / pharmacology*
-
Protein Glutamine gamma Glutamyltransferase 2
-
Reactive Oxygen Species / agonists
-
Reactive Oxygen Species / antagonists & inhibitors
-
Reactive Oxygen Species / metabolism*
-
Receptors, IgG / genetics
-
Receptors, IgG / metabolism
-
Signal Transduction
-
THP-1 Cells
-
Transcription Factor AP-1 / genetics*
-
Transcription Factor AP-1 / metabolism
-
Transglutaminases / antagonists & inhibitors
-
Transglutaminases / genetics*
-
Transglutaminases / metabolism
Substances
-
Amyloid beta-Peptides
-
Butadienes
-
Enzyme Inhibitors
-
FCGR3B protein, human
-
GPI-Linked Proteins
-
IL1B protein, human
-
IL6 protein, human
-
Interleukin-1beta
-
Interleukin-6
-
Lipopolysaccharide Receptors
-
Nitriles
-
Peptide Fragments
-
Reactive Oxygen Species
-
Receptors, IgG
-
Transcription Factor AP-1
-
U 0126
-
amyloid beta-protein (1-42)
-
Genistein
-
Protein Glutamine gamma Glutamyltransferase 2
-
Transglutaminases
-
MAPK1 protein, human
-
Mitogen-Activated Protein Kinase 1
-
Mitogen-Activated Protein Kinase 3
-
MAP Kinase Kinase 4
-
GTP-Binding Proteins